Growth hormone, acting in part through the insulin-like growth factor axis, rescues developmental, but not metabolic, activity in the mammary gland of mice expressing a single allele of the prolactin receptor.
The heterozygous prolactin (PRL) receptor (PRLR(+/-)) mouse fails to develop a fully functional mammary gland at the end of the first pregnancy and shows markedly impaired lobuloalveolar development and milk secretion in young females. PRL and GH, acting through the IGF system, have interactive effects to enhance epithelial cell survival. Thus, we propose that a reduction in the expression of the PRLR may lead to increased IGFBP-5 expression (proapoptotic) and that GH may rescue mammary development by increasing IGF-I, an important mitogen and survival factor for the mammary epithelium. Mammary IGF-binding protein-5 (IGFBP-5) concentrations and plasmin activity in PRLR(+/-) mice were increased on d 2 postpartum, indicative of increased cell death and extracellular matrix remodeling. After GH treatment, a restoration of mammary alveolar development and a reduction in the activities of IGFBP-5 and plasmin were observed. Despite the severely impaired mammary development in PRLR(+/-) mice, both mRNA and protein expression for caseins and acetyl-coenzyme A (acetyl-CoA) carboxylase and acetyl-CoA caboxylase-alpha mRNA increased at parturition, although not to the extent in wild-type animals. Surprisingly, GH treatment actually led to a further decrease in milk protein and acetyl-CoA carboxylase-alphaexpression when expressed per cell. This was confirmed by the smaller alveolar size, the relative paucity of milk in the mammary glands of GH-treated animals, and the inability of their pups to gain weight. In a subsequent study IGFBP-5 was administered to wild-type mice and produced a 45% decrease in mammary DNA content, a 30% decrease in parenchymal tissue, and impaired lactation. These results suggest that GH can improve mammary development in PRLR(+/-) mice, but that it fails to enhance metabolic activity. This may be due to the maintenance by GH/IGF-I of a proliferative, rather than a differentiative, phenotype.
Allan
Gordon J
GJ
Institut National de la Santé et de la Recherche Médicale, Unité 344, Faculté de Médecine Necker, 75730 Paris, France.
Tonner
Elizabeth
E
Barber
Michael C
MC
Travers
Maureen T
MT
Shand
John H
JH
Vernon
Richard G
RG
Kelly
Paul A
PA
Binart
Nadine
N
Flint
David J
DJ
D000103:Acetyl-CoA Carboxylase / Q000235:genetics; D000483:Alleles; D000818:Animals; D017209:Apoptosis; D001940:Breast / Q000254:growth & development* / Q000378:metabolism; D002364:Caseins / Q000235:genetics; D004247:DNA / Q000032:analysis; D004848:Epithelium / Q000502:physiology; D005109:Extracellular Matrix / Q000502:physiology; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism; D015870:Gene Expression; D013006:Growth Hormone / Q000502:physiology*; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000502:physiology*; D007743:Labor, Obstetric; D008297:Male; D051379:Mice; D011247:Pregnancy; D012333:RNA, Messenger / Q000032:analysis; D011981:Receptors, Prolactin / Q000235:genetics* / Q000502:physiology; D015430:Weight Gain
D002364:Caseins; D018975:Insulin-Like Growth Factor Binding Protein 5; D012333:RNA, Messenger; D011981:Receptors, Prolactin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D004247:DNA; D005341:Fibrinolysin; D000103:Acetyl-CoA Carboxylase